Surgery centers are the next focus, President and CEO Martin Bonick told a recent industry conference. But that push is more ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Read here for an analysis of Koninklijke Philips' performance and 2025 outlook, highlighting challenges and revised sales ...

The bank's supplementary leverage ratio was 6.1% at the end of fourth quarter of 2024, in excess of the minimum of 5%. JPMorgan's liabilities are prudently diversified, with more than half of assets ...

The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

TG Therapeutics is entering 2025 with investors accustomed to a beat-and-raise guidance policy and the company needs to ...

What are biopharma VCs looking to invest in this year? Autoimmune disorders, osteoporosis, and cardiovascular disease are ...

During his presentation at the J.P. Morgan Healthcare Conference last week, Incyte CEO Hervé Hoppenot took investors on a ...

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

On this edition of GEN Live, members of the GEN and Inside Precision Medicine (IPM) editorial teams who attended JPM join the ...

We recently compiled a list of the Jim Cramer Recently Discussed These 15 Stocks & The California Wildfires. In this article, ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...